Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
作者信息
Saba Nabil F
机构信息
Hematology and Medical Oncology, Winship Cancer Institute of Emory University , Atlanta, GA , USA.
出版信息
Front Oncol. 2017 Mar 13;7:31. doi: 10.3389/fonc.2017.00031. eCollection 2017.
Abstract
摘要
相似文献
1
Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).评论：杜利戈图单抗（MEHD7945A）与西妥昔单抗治疗头颈部鳞状细胞癌的随机II期研究（MEHGAN研究）。
Front Oncol. 2017 Mar 13;7:31. doi: 10.3389/fonc.2017.00031. eCollection 2017.
2
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).杜利戈图单抗（MEHD7945A）与西妥昔单抗治疗头颈部鳞状细胞癌的随机II期研究（MEHGAN研究）。
Front Oncol. 2016 Oct 31;6:232. doi: 10.3389/fonc.2016.00232. eCollection 2016.
3
Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.MEHD7945A 单药或联合顺铂双重靶向表皮生长因子受体和 HER3 部分克服头颈部鳞状细胞癌细胞系对西妥昔单抗的耐药性。
Cancer Biother Radiopharm. 2017 Sep;32(7):229-238.
4
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.度利妥珠单抗（MEHD7945A）联合顺铂/5-氟尿嘧啶或卡铂/紫杉醇用于一线治疗复发/转移性头颈部鳞状细胞癌的Ib期研究。
Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.
5
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer.Ⅱ期研究：双重 EGFR/HER3 抑制剂杜利妥珠单抗（MEHD7945A）联合 FOLFIRI 二线治疗野生型转移性结直肠癌对比西妥昔单抗。
Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.
6
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.一流的双作用HER3/EGFR抗体MEHD7945A在局部晚期或转移性上皮肿瘤中的安全性及药代动力学/药效学
Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.
7
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.丙戊酸联合顺铂和西妥昔单抗治疗复发和/或转移性头颈部鳞状细胞癌的II期临床研究-V-CHANCE试验
BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y.
8
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.含西妥昔单抗的联合方案用于局部晚期及复发或转移性头颈部鳞状细胞癌
Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019.
9
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).表皮生长因子受体（EGFR）和 ErbB 家族靶向药物在头颈部鳞状细胞癌（HNSCC）治疗中的当前挑战和临床研究。
Cancer Treat Rev. 2014 May;40(4):567-77. doi: 10.1016/j.ctrv.2013.10.002. Epub 2013 Oct 12.
10
The role of cetuximab in the treatment of squamous cell cancer of the head and neck.西妥昔单抗在头颈部鳞状细胞癌治疗中的作用。
Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. doi: 10.1517/14712598.5.8.1085.
引用本文的文献
1
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.CDX-3379与西妥昔单抗联合用于复发/转移性、人乳头瘤病毒阴性、西妥昔单抗耐药头颈部癌的II期试验
Cancers (Basel). 2022 May 10;14(10):2355. doi: 10.3390/cancers14102355.
2
DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.DARPP-32 促进了 EGFR 突变型肺腺癌中 ERBB3 介导的对分子靶向治疗的耐药性。
Oncogene. 2022 Jan;41(1):83-98. doi: 10.1038/s41388-021-02028-5. Epub 2021 Oct 21.
3
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.癌症治疗中靶向双肿瘤相关抗原的双特异性抗体。
J Cancer Res Clin Oncol. 2020 Dec;146(12):3111-3122. doi: 10.1007/s00432-020-03404-6. Epub 2020 Sep 28.
4
Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysis.Her3过表达与结直肠癌临床病理及预后的相关性：一项Meta分析
Medicine (Baltimore). 2018 Sep;97(37):e12317. doi: 10.1097/MD.0000000000012317.
5
Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.白细胞介素-6/信号转导和转录激活因子3信号通路在p16阴性口咽鳞状细胞癌中显著存在，并与总生存期缩短相关。
Head Neck Pathol. 2019 Sep;13(3):304-312. doi: 10.1007/s12105-018-0962-y. Epub 2018 Sep 6.
6
Imaging EGFR and HER3 through Zr-labeled MEHD7945A (Duligotuzumab).通过 Zr 标记的 MEHD7945A（杜利古妥珠单抗）进行 EGFR 和 HER3 成像。
Sci Rep. 2018 Jun 13;8(1):9043. doi: 10.1038/s41598-018-27454-6.
本文引用的文献
1
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).杜利戈图单抗（MEHD7945A）与西妥昔单抗治疗头颈部鳞状细胞癌的随机II期研究（MEHGAN研究）。
Front Oncol. 2016 Oct 31;6:232. doi: 10.3389/fonc.2016.00232. eCollection 2016.
2
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.靶向HER3通过降低HER3活性和HER2/HER3二聚化使头颈部鳞状细胞癌对西妥昔单抗敏感：来自细胞系和患者来源异种移植模型的证据
Clin Cancer Res. 2017 Feb 1;23(3):677-686. doi: 10.1158/1078-0432.CCR-16-0558. Epub 2016 Jun 29.
3
Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.Heregulin和HER3是口咽鳞状细胞癌的预后生物标志物。
Cancer. 2015 Oct 15;121(20):3600-11. doi: 10.1002/cncr.29549. Epub 2015 Jul 20.
4
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.阿法替尼对比甲氨蝶呤用于铂类治疗后进展的复发性或转移性头颈部鳞状细胞癌患者的二线治疗（LUX-Head & Neck 1）：一项开放标签、随机、III 期研究。
Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.
5
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.抗HER3抗体MM-121/SAR256212与西妥昔单抗联合使用可抑制头颈部鳞状细胞癌临床前模型中的肿瘤生长。
Mol Cancer Ther. 2014 Jul;13(7):1826-36. doi: 10.1158/1535-7163.MCT-13-1093. Epub 2014 Apr 18.
6
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.西妥昔单抗获得性耐药机制：HER（ErbB）家族成员的作用
Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19. Epub 2008 Feb 25.
Zotero 插件